IDEXX Laboratories, Inc. (NASDAQ:IDXX) Holdings Decreased by Envestnet Portfolio Solutions Inc.

Envestnet Portfolio Solutions Inc. reduced its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 10.1% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 16,649 shares of the company's stock after selling 1,875 shares during the period. Envestnet Portfolio Solutions Inc.'s holdings in IDEXX Laboratories were worth $6,992,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in shares of IDEXX Laboratories during the 4th quarter worth approximately $412,258,000. GAMMA Investing LLC grew its stake in IDEXX Laboratories by 59,810.7% during the 1st quarter. GAMMA Investing LLC now owns 918,431 shares of the company's stock worth $3,856,950,000 after buying an additional 916,898 shares during the last quarter. Alyeska Investment Group L.P. acquired a new stake in IDEXX Laboratories in the fourth quarter worth $156,412,000. William Blair Investment Management LLC increased its position in IDEXX Laboratories by 701.6% in the fourth quarter. William Blair Investment Management LLC now owns 422,133 shares of the company's stock worth $174,527,000 after buying an additional 369,471 shares during the period. Finally, BNP Paribas Financial Markets lifted its stake in IDEXX Laboratories by 221.3% in the fourth quarter. BNP Paribas Financial Markets now owns 441,319 shares of the company's stock valued at $182,459,000 after buying an additional 303,966 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX opened at $523.92 on Friday. The stock has a market cap of $42.13 billion, a price-to-earnings ratio of 48.42, a PEG ratio of 3.80 and a beta of 1.55. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.16 and a quick ratio of 0.81. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $530.73. The stock's 50 day moving average price is $486.81 and its 200 day moving average price is $447.64.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported $2.96 EPS for the quarter, topping analysts' consensus estimates of $2.93 by $0.03. The company had revenue of $998.43 million for the quarter, compared to the consensus estimate of $998.25 million. IDEXX Laboratories had a return on equity of 57.35% and a net margin of 22.76%. The company's quarterly revenue was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.71 EPS. Equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on IDXX. Stifel Nicolaus increased their price objective on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the stock a "hold" rating in a report on Monday, May 19th. Wall Street Zen lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. Leerink Partners boosted their price objective on IDEXX Laboratories from $515.00 to $580.00 and gave the stock an "outperform" rating in a research report on Wednesday, June 11th. Finally, Morgan Stanley increased their price objective on IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a report on Monday, May 5th. Four equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $546.00.

Insider Activity at IDEXX Laboratories

In related news, Director M Anne Szostak sold 1,260 shares of the stock in a transaction that occurred on Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total value of $645,548.40. Following the transaction, the director now owns 1,801 shares in the company, valued at approximately $922,724.34. This represents a 41.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.98% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.